Race and long-acting antipsychotic prescription at a community mental health center: a retrospective chart review.

The Journal of Clinical Psychiatry
Neil Krishan AggarwalMichael J Sernyak

Abstract

There has been concern that racial minorities are disproportionately prescribed long-acting injectable antipsychotic drugs. Comprehensive administrative data and clinician survey were used to identify all patients with a DSM-IV diagnosis of schizophrenia who received long-acting antipsychotic prescriptions from July 2009 to June 2010 at a community mental health center. Charts were reviewed retrospectively to validate long-acting antipsychotic prescription (eg, medication, dosage) and merged with administrative data from all center patients documenting sociodemographic characteristics (ie, age, race, gender) and comorbid diagnoses. We used bivariate χ2, t tests, and multivariate logistic regression to compare the subsample of patients receiving long-acting injectable drugs (n = 102) to patients not receiving long-acting injectable drugs (n = 799) who were diagnosed with schizophrenia for the same period. White patients were significantly less likely to receive long-acting antipsychotic prescriptions than minority patients (OR = 0.52, P < .007); ie, nonwhites were 1.89 times more likely to receive such drugs. Age, gender, and comorbid diagnoses, including substance abuse, were unrelated to long-acting injectable prescription, an...Continue Reading

References

Jun 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·R MacphersonA Hughes
Jun 10, 2000·The Journal of Clinical Psychiatry·J T WalkupS Hansell
Apr 2, 2002·The American Journal of Psychiatry·Eri Kuno, Aileen B Rothbard
Aug 26, 2003·American Journal of Medical Quality : the Official Journal of the American College of Medical Quality·Richard R OwenBrenda M Booth
Oct 14, 2003·Schizophrenia Bulletin·Julie KreyenbuhlAnthony F Lehman
Apr 6, 2004·Schizophrenia Research·Lesley M ArnoldJenni E Farrow
Sep 6, 2005·Community Mental Health Journal·Esperanza DiazRobert A Rosenheck
Aug 8, 2006·The Journal of Clinical Psychiatry·Haya Ascher-SvanumChristian R Dolder
Oct 5, 2006·The Journal of Clinical Psychiatry·Deanna L KellyRobert R Conley
Nov 17, 2006·The Journal of Clinical Psychiatry·Marcia ValensteinFrederic C Blow
Apr 7, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·William M Glazer
Apr 7, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Lizheng ShiStephen R Marder
Dec 18, 2007·Psychiatry and Clinical Neurosciences·Gobind ChabungbamPratap Sharan
Dec 21, 2007·Schizophrenia Bulletin·Joyce C WestMark Olfson
May 6, 2009·Health Affairs·Jeffrey SwansonPamela Clark Robbins
May 28, 2010·The British Journal of Psychiatry. Supplement·Thomas R E BarnesCarol Paton
May 28, 2010·The British Journal of Psychiatry. Supplement·John M Kane, Carlos Garcia-Ribera

❮ Previous
Next ❯

Citations

Oct 17, 2014·American Journal of Public Health·Jennifer M Reingle Gonzalez, Nadine M Connell
Jul 2, 2015·Pharmacoepidemiology and Drug Safety·Thomas B CookTeodor T Postolache
Oct 10, 2015·Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry·Neil Krishan AggarwalRoberto Lewis-Fernández
Nov 12, 2017·Community Mental Health Journal·Robert O CotesBenjamin G Druss
Feb 10, 2017·International Clinical Psychopharmacology·Taishiro KishimotoJohn M Kane
Apr 16, 2017·Journal of Racial and Ethnic Health Disparities·Mana K AliJulie A Kreyenbuhl
Sep 4, 2020·Human Molecular Genetics·Hillary R DueñasLaura M Huckins
Mar 30, 2021·Expert Opinion on Drug Safety·Renato de FilippisMaria Rosaria Anna Muscatello

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here